Expert Discusses Home Treatment for Aggressive Lymphomas Amidst COVID-19 Pandemic

Article

Stephen Schuster, MD, explained how Penn Medicine is utilizing at-home treatments, which will continue after the pandemic, to maximize safety and reduce hospital traffic during the COVID-19 pandemic.

Stephen Schuster, MD, explained how Penn Medicine is utilizing at-home treatments, which will continue after the pandemic, to maximize safety and reduce hospital traffic during the COVID-19 pandemic.

Transcription:

We’ve also set up to do many of our treatments at home that we used to hospitalize patients for. For example, patients that require infusional chemotherapy, not bolus, like R-EPOCH, we now do it at home. We have all the SOPs working fine and have not had any unforeseen or adverse events occur in the home setting, and patients seem to like it. I think the silver lining in all of this is that as we begin to open up again, we’re probably going to maintain a lot of the procedures that we’ve implemented. For example, in terms of cleaning and trying to stagger patients, I think this has been a learning experience. We’ve done very well without observing any complications. So, I think that we’ll continue to maintain-I mean it’ll just be as important during flu season, etc. to try to stagger visits, do extra cleaning, and then to treat patients at home. The ability to do televisits is very convenient for patients when they don’t actually have to be examined, or they’re not having a problem where it’s a routine follow up, touching bases, review labs, reviewing images with the patients. It’s a great way to do it. Now that we have the technology up and running, I don’t think it’s going to disappear.

Related Videos
The education of patients on identifying and reporting adverse effects is a critical part of effective toxicity management.
One role of a physician assistant is to help patients understand their treatment and the results they’re presented with.
Adverse effect management is a concern for clinicians when administering follicular lymphoma treatment, and the use of targeted pathways may help mitigate them.
Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Experts on GVHD with a patient
Experts on GVHD with a patient
Experts on GVHD
Experts on GVHD
Experts on GVHD with a patient
Experts on GVHD with a patient
Related Content